Description
Composition:
Each BECIADIC® 10 mg coated tablet contains: Empagliflozina 10 mg. Excipientes: Lactosa monohidrato, Celulosa microcristalina, Hidroxipropilcelulosa, Croscarmelosa sódica, Dióxido de silicio coloidal. Estearato de magnesio, Lay AQ P50204P (corresponde a Alcohol polivinílico, Polietilenglicol 3350, Talco, Dióxido de titanio).
Each BECIADIC® 25 mg coated tablet contains: Empagliflozina 25 mg. Excipientes: Lactosa monohidrato, Celulosa microcristalina, Hidroxipropilcelulosa, Croscarmelosa sódica, Dióxido de silicio coloidal. Estearato de magnesio, Lay AQ P50204P (corresponde a Alcohol polivinílico, Polietilenglicol 3350, Talco, Dióxido de titanio), Colorante amarillo de Quinolina Laca lumínica.
Terapheutic Action: ATC code: A10BK03. Oral hypoglycemic agent, sodium-glucose cotransporter type 2 (SGLT2) inhibitor.
Indications: BECIADIC® is a sodium-glucose cotransporter type 2 (SGLT2) inhibitor indicated for:
- Type 2 Diabetes mellitus
- BECIADIC® is indicated in adults and children 10 years of age and older for the treatment of type 2 diabetes mellitus not sufficiently controlle with diet and exercise.
- As monotherapy, when metformin is not considered appropriate due to intolerance.
- In combination with other medications for the treatment of diabetes.
- Heart Failure
- BECIADIC® is indicated in adults for the treatment of symptomatic chronic heart failure.
- Chronic Kidney Disease
- BECIADIC® is indicated in adults for the treatment of chronic kidney disease.
Presentaciones
BECIADIC® 10 mg package containing 30 coated tablets
BECIADIC® 25 mg package containing 30 coated tablets
